You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍捱沽 榮昌生物(09995.HK)挫一成6
恆指今天在權重新經濟股拖累反覆回軟,現報15,372,反覆跌19點或0.1%,總成交額511億元。 醫藥股今天普遍捱沽,榮昌生物(09995.HK)挫10%報24.1元,該公司昨天澄清網上評論指公司現金流緊缺及面臨訴訟風等內容不實。來凱醫藥-B(02105.HK)三連跌,最低見11.02元創逾四個月低,現報11.4元,續跌6.5%。 康龍化成(03759.HK)、信達生物(01801.HK)及康方生物(09926.HK)跌5%-7%,前者股價曾見12元創上市新低,後者沽壓最大報42.15元。 屢創上市新低康寧傑瑞製藥-B(09966.HK)、騰盛博藥-B(02137.HK)、康諾亞-B(02162.HK)、宜明昂科-B(01541.HK)、綠葉製藥(02186.HK)、金斯瑞(01548.HK)、百濟神州(06160.HK)、藍籌國藥(01099.HK)、石藥(01093.HK)、中生(01177.HK)、翰森(03692.HK)、藥明合聯(02268.HK)、雲頂新耀-B(01952.HK)、康希諾生物(06185.HK)及維亞生物(01873.HK)跌逾2%-3.5%,後者曾見0.72元上市新低。 然而、聯邦制藥(03933.HK)及藍籌藥明康德(02359.HK)反覆逆市續升逾1.5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account